Ivicentamab
Based on 1 Customer Validation
Ivicentamab (GEN-3009) is a bispecific antibody targeting CD37 with dual epitopes. Ivicentamab carries an E430G mutation in the Fc region, which efficiently promotes IgG hexamer formation on the surface of target cells. Ivicentamab provides the parental variable regions for an H429F-engineered anti-CD37 bispecific antibody, enabling it to exert complement-dependent cytotoxicity in Daudi lymphoma cells. Ivicentamab is mainly used in lymphoma-related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.82%
- CAS No.: 2364496-42-2
- Masse moléculaire:144.88 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Human IgG1 kappa
Human
CD37
Ivicentamab provides the parental variable regions for an H429F-engineered anti-CD37 bispecific antibody that promotes on-target IgG hexamerization and enhances complement-dependent cytotoxicity in Daudi lymphoma cells[1].
Ivicentamab-derived biparatopic bispecific anti-CD37 antibody (0.0–1.0 μg/mL) enhances complement-dependent cytotoxicity in Daudi lymphoma cells and mediates potent target cell lysis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized CD37 Protein, Human (HEK293, Fc, HY-P77886) can bind Ivicentamab. The EC50 for this effect is 7.22 ng/mL.
Chemical Information
-
CAS No. 2364496-42-2
-
Appearance Liquid
-
Masse moléculaire 144.88 kDa
-
Color Colorless to light yellow
-
SMILES
[Ivicentamab]
-
Synonyms
GEN-3009
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)